

3rd November, 2025

To,

**The Corporate Relationship Department
BSE Limited**
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001.
Scrip Code: 539523

National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra East ,
Mumbai 400 051.
Scrip Symbol: ALKEM

**Sub: Press Release – Alkem and IIT Bombay announce strategic collaboration to set up
advanced research centre for immuno-therapeutics and regenerative medicines**

Dear Sir(s)/Madam,

This is to intimate you that Alkem Foundation, the Corporate Social Responsibility (CSR) arm of Alkem Laboratories Ltd. (“the Company”), and Indian Institute of Technology Bombay (“IIT Bombay”) announces a strategic collaboration to set up a first-of-its-kind research centre in India dedicated to immuno-therapeutics and regenerative medicines.

A press release in this regard is enclosed herewith.

Kindly take the same on record.

Sincerely,

For **Alkem Laboratories Limited**

Manish Narang

President- Legal, Company Secretary and Compliance Officer

Press Release

Alkem Foundation and IIT Bombay announce strategic collaboration to set up advanced research centre for immuno-therapeutics and regenerative medicines

Mumbai, November 3, 2025: Alkem Foundation, the Corporate Social Responsibility (CSR) arm of Alkem Laboratories Ltd. (“Alkem”), and Indian Institute of Technology Bombay (“IIT Bombay”) today announced a strategic collaboration to set up a first-of-its-kind research centre in India dedicated to immuno-therapeutics and regenerative medicines.

Under this collaboration, Alkem Foundation will fund the establishment of “Alkem Centre for Advanced Research and Development of Applied Immuno-Therapeutics and Regenerative Medicines” in the IIT Bombay campus. This is a pioneering step in fostering cutting-edge research and innovation in complex disease areas, which have significant unmet medical needs. Alkem Foundation will contribute a substantial 20-25% of its cumulative CSR obligations over seven years on this research centre.

This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines. The partnership brings together Alkem’s pharmaceutical industry insights and experience in developing healthcare solutions, and IIT Bombay’s expertise in biomedical engineering, biosciences, and translational research, along with a pool of globally trained faculty, to create a distinctive innovation and translation ecosystem.

The research centre is being developed with an objective of building a comprehensive ecosystem that enables innovation, research, and skill development in complex and underserved therapy areas, and bridging critical gaps in infrastructure, talent, and translational capability, especially in the area of high precision medicines.

The initiative will augment IIT Bombay’s multidisciplinary approach to healthcare integrating biology, engineering, and data science to advance human health. The Institute’s pioneering research spans biotechnology, biomedical engineering, and cell and gene therapy, forming the foundation for next-generation immuno-therapeutics and regenerative medicine.

Building on this strong foundation, the new research centre will expand into emerging areas such as gene editing and biomaterials and technology to bolster immuno-therapeutics and regenerative medicines using unique models based on futuristic techniques for delivery and edition. It will also serve as a training and incubation hub for clinician-scientists and biotech entrepreneurs, strengthening India's translational research ecosystem in life sciences. It will draw upon IIT Bombay's core faculty and have mentors from IIT Bombay and Alkem, as well as global experts from premier universities, who will advise on the research programmes.

Mrs. Madhurima Singh, Executive Director and Chairperson of the CSR and Sustainability Committee, Alkem, said, “At Alkem, we understand the critical role of scientific advancement and transformative research in addressing unmet medical needs. Despite government encouragement, only a small share of corporate CSR spending in India

goes towards R&D. We saw it as our responsibility to go beyond business and support R&D in the important field of immuno-therapeutics and regenerative medicines through CSR. We are pleased to partner with IIT Bombay, a prestigious institution that has been at the forefront of India's innovation and self-reliance efforts, to develop advanced and cost-effective treatments that can improve both lifespan and quality of life. This partnership reflects our shared commitment to developing healthcare solutions by India for India and the world."

Prof. Shireesh B. Kedare, Director, IIT Bombay, said, "We are delighted to partner with Alkem Foundation in this transformative initiative. IIT Bombay's strong foundation in biotechnology, biomedical engineering, and regenerative sciences positions us to translate cutting-edge research into real-world healthcare impact. This collaboration will foster clinical breakthroughs that lead to affordable therapies, reduce dependence on imports, and take us a step further in India's journey toward self-reliance in healthcare innovation."

Together, IIT Bombay and Alkem Foundation aim to create a national model for industry-academia partnerships that advance affordable, high-impact healthcare innovation and position India as a global leader in applied biotechnology.

About Alkem Foundation:

Alkem Foundation is the Corporate Social Responsibility (CSR) arm of Alkem Laboratories Ltd. The key thematic areas that Alkem Foundation focuses on are Healthcare, Research & Innovation, Environment and Sustainability initiatives, Integrated Village Development, and Sports. The endeavour of Alkem Foundation to bring about a tangible change in the lives of underprivileged people and improve people's quality of life by facilitating the implementation of holistic community development programmes. Alkem Foundation undertakes initiatives with a participatory approach and in collaboration mode with the government, civil society, and the community at a large.

About Alkem:

Alkem Laboratories Ltd. is a leading Indian pharmaceutical company with a legacy of 50 years in providing high quality medicines to patients. It is the fifth largest pharmaceutical company in the Indian market with a dominant position in the therapy areas of anti-infectives, gastrointestinal, pain management drugs and supplements. It also has a growing portfolio of products in chronic therapies such as diabetes, neurology, cardiology, dermatology and urology. It has 19 state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centers across India and the US to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has meaningful presence in the US, Latin America, Australia and several Asian countries. "Inspiring Healthier Lives" is at the core of the values and culture of the organisation and reinforces its steadfast commitment to global health improvement. For more information, please visit www.alkemlabs.com and follow us on [LinkedIn](#), [Instagram](#), [Facebook](#).

About IIT Bombay:

The Indian Institute of Technology Bombay, set up in 1958 as the second IIT, is recognised worldwide as a leader in the field of science and engineering education and research. The Institute was granted the status of 'Institution of Eminence' by the Ministry of Education (the then Ministry of Human Resources Development) on July 9, 2018. IIT Bombay is reputed for the quality of its faculty and the outstanding calibre of students graduating from its undergraduate and postgraduate programmes. The Institute has 17 academic departments, 31 Centres/ Programmes/ Academic facilities and three schools. Over the last

six decades, more than 70,000 engineers and scientists have graduated from the Institute. It is served by more than 756 faculty members, with 121 women faculty, considered not only amongst the best within the country but also highly recognised in the world for achievements in the field of education and research. In June 2025, IIT Bombay was ranked 2nd in India and 129th in the world in the Quacquarelli Symonds (QS) World University Rankings for 2026. In March 2025, IIT Bombay was ranked 28th in Engineering and Technology in the Quacquarelli Symonds (QS) World University Rankings by Subject for 2025.

Contacts

Media:

Isha Trivedi

alkemcorpcomm@alkem.com

+91-98925 90003

Investors:

Purvi Shah

purvi.shah@alkem.com

+91-84337 00890